---
title: "IMMUNIC, INC. 1Q 2026: Revenue $0 Net loss $32.6M — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286244201.md"
description: "IMMUNIC, INC. reported Q1 2026 results with $0 revenue and a net loss of $32.6M, widening from a $25.5M loss in Q1 2025. The company is advancing clinical programs, including fully enrolled Phase 3 ENSURE trials for vidofludimus calcium. Positive Phase 2 results for IMU-381 and IMU-856 were noted. R&D operations have centralized in Germany, and a key European patent was granted, extending protection into 2038. The company is exploring partnerships and licensing opportunities."
datetime: "2026-05-13T10:41:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286244201.md)
  - [en](https://longbridge.com/en/news/286244201.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286244201.md)
---

# IMMUNIC, INC. 1Q 2026: Revenue $0 Net loss $32.6M — 10-Q Summary

IMMUNIC, INC. reported first-quarter 2026 results with no product revenue and a wider net loss versus the prior-year quarter as the company continues to advance multiple clinical programs.

**Financial Highlights**

-   Revenue was $0 for Q1 2026 (no product sales; the company has not generated revenue to date).
-   Net loss was $32.6M for Q1 2026, compared with a net loss of $25.5M in Q1 2025; year-over-year loss increased (28%).
-   Diluted earnings per share: Not reported for Q1 2026 in Part I Items 1–2 and therefore omitted.

**Business Highlights**

-   Clinical advancement: Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis are fully enrolled at about 2,221 patients; top-line data are expected by the end of 2026.
-   Pipeline progress: Positive Phase 2 CALLIPER results in progressive MS and ongoing preclinical work on IMU-381; IMU-856 showed positive Phase 1b celiac data and the company is exploring strategic alternatives for that program.
-   Operational expansion: R&D has been centralized in Gräfelfing, Germany, with labs in Martinsried/Halle and an Australian subsidiary in Melbourne; the company reported approximately 95 employees as of April 30, 2026.
-   Strategic and IP moves: IMMUNIC was granted a key European patent covering dosing regimens extending protection into 2038 with potential supplementary protection certificate to 2043, and is exploring partnerships and licensing opportunities across programs.

Original SEC Filing: IMMUNIC, INC. \[ IMUX \] - 10-Q - May. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IMUX.US](https://longbridge.com/en/quote/IMUX.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push](https://longbridge.com/en/news/286623100.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)